Skip to content

Arcturus Therapeutics vs etherna

Arcturus Therapeutics logo

Arcturus Therapeutics

A messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics

155 employees · est. 2013 · San Diego, United States

VS
etherna logo

etherna

Enabling Nucleic Acid Medicines for Next‑Generation Therapies | www.etherna.be

96 employees · est. 2013 · Niel, Belgium

Side-by-Side Comparison

Arcturus Therapeutics etherna
Founded
2013 2013
Headquarters
San Diego, United States Niel, Belgium
Employees
155 96
Industry
Biotechnology, Health Care, Health and Wellness Biotechnology, Health Care, Health and Wellness
Funding Stage
Grant Acquired
Total Funding
$489.58M $104.90M
Funding Rounds
9 7
Services
Not tracked yet LNP platforms development, mRNA platforms development, RNA chemistry expertise, Technology partnering, Product partnering, Pipeline development, Manufacturing solutions
Target Customers
Not tracked yet Pharmaceutical companies, Biotech companies, Start-up projects, Early-stage projects, Late-stage projects
Taxonomy
MRNA MedicinesVaccinesLUNAR® Lipid-mediated DeliverySTARR® MRNA TechnologyMRNA Drug SubstanceDrug Product Manufacturing +8 Nucleic Acid MedicinesRNA ChemistryLNP FormulationNucleic Acid TherapeuticsMRNA ProductionDrug Product Production +9
Website
arcturusrx.com etherna.be
Arcturus Therapeutics logo

About Arcturus Therapeutics

Arcturus Therapeutics is a global late-stage clinical messenger RNA medicines company based in San Diego, California. Founded in 2013, it operates in the Biotechnology and Health Care industries. Arcturus specializes in the development of mRNA medicines and vaccines, utilizing innovative technologie...

etherna logo

About etherna

etherna, founded in 2013, is a pioneering company in the domain of nucleic acid–based medicine technology, headquartered in Belgium. The company operates a platform that addresses the intricate challenges of RNA chemistry and LNP formulation, effectively supporting both emerging and established play...

Also comparing in this category

Comparing more than these two?

Get Arcturus Therapeutics, etherna and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does Arcturus Therapeutics compare?

A PDF of Arcturus Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Rival Readout

Comparing competitors? We do this properly.

10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.

Frequently Asked Questions

Arcturus Therapeutics was founded in 2013, based in San Diego, United States, with 155 employees. Arcturus Therapeutics is a global late-stage clinical messenger RNA medicines company based in San Diego, California. Founded in 2013, it operates in the Biotechnology and Health Care industries. Arct. etherna was founded in 2013, based in Niel, Belgium, with 96 employees. etherna, founded in 2013, is a pioneering company in the domain of nucleic acid–based medicine technology, headquartered in Belgium. The company operates a platform that addresses the intricate challe.
Arcturus Therapeutics has raised $489.58M and etherna $104.90M. Latest stage: Arcturus Therapeutics Grant, etherna Acquired.
Both work in Biotechnology, Health Care and Health and Wellness and list nucleic acid medicines among their focus areas.

Compare Arcturus Therapeutics with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Arcturus Therapeutics on 9 Jun 2026, and etherna on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout